ClinicalTrials.gg
TerminatedNCT01260194Updated Nov 2, 2016Results posted

A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer

A Phase 4 interventional study of trastuzumab [Herceptin] in Gastric Cancer, sponsored by Hoffmann-La Roche. Terminated at 6 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing trastuzumab in Stomach Neoplasms — 8 open to participants now, 10 under way, none of them phase 3. Trastuzumab · Stomach Neoplasms.

Enrollment
37th of 39
4 · median 40
Started
2011
with 7 others
Phase 4
2 of 40
none open now
Registered
5th of 40
by date
Lead sponsor
6 of 40
Hoffmann-La Roche

Among the 40 studies testing trastuzumab in Stomach Neoplasms, this one is the 37th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2011, is one of 2 in phase 4, and was the 5th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 40 studies testing trastuzumab in Stomach Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing trastuzumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

This open-label, multi-center study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with standard chemotherapy as first-line treatment in patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction. Patients will receive standard chemotherapy for a maximum of 6 cycles, and 8 mg/kg Herceptin as loading dose on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/=18 years of age
  • confirmed adenocarcinoma of the stomach or gastro-esophageal junction with advanced or disease, not amenable to curative therapy
  • , according to the (RECIST)
  • positive tumor (primary tumor or metastasis
  • Performance status 0, 1 or 2
  • of at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Previous chemotherapy for advanced or disease less than 6 month before study start
  • Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome (patients with partial or total gastrectomy are allowed to participate in the study)
  • Patients with active (significant or uncontrolled) gastrointestinal bleeding
  • Residual relevant toxicity resulting from previous chemotherapy
  • Other within the last 5 years (except carcinoma in situ of the cervix, or basal cell carcinoma)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    1

    Drug: trastuzumab [Herceptin]

Interventions

  • Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy

06

What researchers measure

Primary outcomes

  1. Median Progression Free Survival (PFS)

    The PFS was defined as the median time between the day of enrollment and the first documentation of progressive disease (PD) or date of death, whichever occurred first. PD was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeters \[mm\]) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. The censoring date was the last date of "last tumor measurement," "last date of study drug treatment," or "last follow-up." The median PFS time with 95% confidence interval (CI) was estimated using Kaplan Meier method.

    Time frame: Baseline up to PD or death (maximum up to 22 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of enrollment to the date of the death (from any cause). If no death was observed, censored observations were taken into account in the analysis. The censoring date was the last date of "last tumor measurement," "last date in drug log," or "last follow-up." The median overall survival time with 95% CI was estimated using Kaplan Meier method.

    Time frame: Baseline up to death (maximum up to 22 months)

  2. Percentage of Participants With Overall Tumor Response

    Overall tumor response was defined as the occurrence of either a confirmed complete response (CR) or a partial response (PR) as best overall response as determined by the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version (v) 1.1 from confirmed radio-graphic evaluations of target and non-target lesions. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease; all nodes, both target and non-target, must decrease to normal (short axis less than \[\<\]10 mm); no new lesions. PR was defined as greater than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions (the short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions); no unequivocal progression of non-target disease; no new lesions.

    Time frame: Baseline up to PD or death (maximum up to 22 months)

  3. Percentage of Participants With Clinical Benefit Response (CBR)

    CBR was defined as any response among stable disease (SD) for 6 weeks or longer, CR, or PR as determined by the RECIST v 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease; all nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions (the short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions); no unequivocal progression of non-target disease; no new lesions. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. SD was defined as not qualifying for CR, PR, or PD.

    Time frame: Baseline up to PD or death (maximum up to 22 months)

  4. Duration of Response (DR)

    DR was based on RECIST criteria v1.1 and was defined as time from date the CR or PR was first recorded to the date on which PD was first noted. CR: complete disappearance of all target lesions and non-target disease, with the exception of nodal disease; all nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR: \>=30% decrease under baseline of the sum of diameters of all target lesions; no unequivocal progression of non-target disease; no new lesions. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions and/or appearance of 1 or more new lesions. For the participants with no documented progression after CR or PR, the censored date (the date of "death," the "last tumor measurement," "last date in drug log," or "last follow-up") was taken into consideration. The median duration of response with 95% CI was estimated using Kaplan Meier method.

    Time frame: Baseline up to PD or death (maximum up to 22 months)

  5. Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in participant hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non-serious AEs.

    Time frame: Baseline up to 6 month after last dose of study drug (maximum up to 22 months)

  6. Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

    Lab parameters assessed during the study were serum chemistry, biochemistry - serum electrolytes, hematology, 12 lead electrocardiogram, and urinalysis - protein, glucose, blood and other lab tests. Laboratory tests were graded according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) version 3.

    Time frame: Baseline up to 6 month after last dose of study drug (maximum up to 22 months)

  7. Number of Participants With Clinically Significant Change From Baseline in Left Ventricular Ejection Fraction (LVEF)

    The LVEF was measured using Multi Gated Acquisition (MUGA) or echocardiography (echocardiography was preferred), using the same technique throughout for consistency in an individual participant. Baseline LVEF assessments were done within 21 days prior to the start of treatment. Participants with clinically significant change from baseline (that is, absolute drop in LVEF of \>=15%, and drop to a value \<50%) have been reported.

    Time frame: Baseline, thereafter every 12 weeks (maximum up to 22 months)

  8. Number of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Gastric Cancer

    The HER2 status was determination by using immunohistochemistry (IHC) and confirmatory Fluorescent In Situ Hybridization (FISH) techniques. Only participants with HER2 positivity were allowed to receive study medication.

    Time frame: Baseline

07

Results

Posted Mar 14, 2016

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab
Started4
Completed3
Not completed1
Withdrew: Withdrawal of consent1

Outcome measures

PrimaryMedian Progression Free Survival (PFS)

The PFS was defined as the median time between the day of enrollment and the first documentation of progressive disease (PD) or date of death, whichever occurred first. PD was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeters \[mm\]) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. The censoring date was the last date of "last tumor measurement," "last date of study drug treatment," or "last follow-up." The median PFS time with 95% confidence interval (CI) was estimated using Kaplan Meier method.

Time frame:
Baseline up to PD or death (maximum up to 22 months)
Reported as:
Median · days
Median Progression Free Survival (PFS)
daysTrastuzumab
Median Progression Free Survival (PFS)254.0 (52.0 to 508.0)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of enrollment to the date of the death (from any cause). If no death was observed, censored observations were taken into account in the analysis. The censoring date was the last date of "last tumor measurement," "last date in drug log," or "last follow-up." The median overall survival time with 95% CI was estimated using Kaplan Meier method.

Time frame:
Baseline up to death (maximum up to 22 months)
Reported as:
Median · days
Overall Survival (OS)
daysTrastuzumab
Overall Survival (OS)508.0 (82.0 to NA)
SecondaryPercentage of Participants With Overall Tumor Response

Overall tumor response was defined as the occurrence of either a confirmed complete response (CR) or a partial response (PR) as best overall response as determined by the Response Evaluation Criteria In Solid Tumors (RECIST) criteria version (v) 1.1 from confirmed radio-graphic evaluations of target and non-target lesions. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease; all nodes, both target and non-target, must decrease to normal (short axis less than \[\<\]10 mm); no new lesions. PR was defined as greater than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions (the short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions); no unequivocal progression of non-target disease; no new lesions.

Time frame:
Baseline up to PD or death (maximum up to 22 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Tumor Response
percentage of participantsTrastuzumab
Percentage of Participants With Overall Tumor Response50 (9.4 to 99.2)
SecondaryPercentage of Participants With Clinical Benefit Response (CBR)

CBR was defined as any response among stable disease (SD) for 6 weeks or longer, CR, or PR as determined by the RECIST v 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease; all nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions (the short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions); no unequivocal progression of non-target disease; no new lesions. PD was defined as at least 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. SD was defined as not qualifying for CR, PR, or PD.

Time frame:
Baseline up to PD or death (maximum up to 22 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Benefit Response (CBR)
percentage of participantsTrastuzumab
Percentage of Participants With Clinical Benefit Response (CBR)75.0 (29.2 to 100.0)
SecondaryDuration of Response (DR)

DR was based on RECIST criteria v1.1 and was defined as time from date the CR or PR was first recorded to the date on which PD was first noted. CR: complete disappearance of all target lesions and non-target disease, with the exception of nodal disease; all nodes, both target and non-target, must decrease to normal (short axis \<10 mm); no new lesions. PR: \>=30% decrease under baseline of the sum of diameters of all target lesions; no unequivocal progression of non-target disease; no new lesions. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions and/or appearance of 1 or more new lesions. For the participants with no documented progression after CR or PR, the censored date (the date of "death," the "last tumor measurement," "last date in drug log," or "last follow-up") was taken into consideration. The median duration of response with 95% CI was estimated using Kaplan Meier method.

Time frame:
Baseline up to PD or death (maximum up to 22 months)
Reported as:
Median · days
Duration of Response (DR)
daysTrastuzumab
Duration of Response (DR)NA (NA to NA)
SecondaryNumber of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in participant hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non-serious AEs.

Time frame:
Baseline up to 6 month after last dose of study drug (maximum up to 22 months)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
participantsTrastuzumab
AEs4
SAEs2
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

Lab parameters assessed during the study were serum chemistry, biochemistry - serum electrolytes, hematology, 12 lead electrocardiogram, and urinalysis - protein, glucose, blood and other lab tests. Laboratory tests were graded according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) version 3.

Time frame:
Baseline up to 6 month after last dose of study drug (maximum up to 22 months)
Reported as:
Number · participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters
participantsTrastuzumab
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters0
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Left Ventricular Ejection Fraction (LVEF)

The LVEF was measured using Multi Gated Acquisition (MUGA) or echocardiography (echocardiography was preferred), using the same technique throughout for consistency in an individual participant. Baseline LVEF assessments were done within 21 days prior to the start of treatment. Participants with clinically significant change from baseline (that is, absolute drop in LVEF of \>=15%, and drop to a value \<50%) have been reported.

Time frame:
Baseline, thereafter every 12 weeks (maximum up to 22 months)
Reported as:
Number · participants
Number of Participants With Clinically Significant Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
participantsTrastuzumab
Number of Participants With Clinically Significant Change From Baseline in Left Ventricular Ejection Fraction (LVEF)0
SecondaryNumber of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Gastric Cancer

The HER2 status was determination by using immunohistochemistry (IHC) and confirmatory Fluorescent In Situ Hybridization (FISH) techniques. Only participants with HER2 positivity were allowed to receive study medication.

Time frame:
Baseline
Reported as:
Number · participants
Number of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Gastric Cancer
participantsTrastuzumab
Number of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Gastric Cancer4

Adverse events

Collected over 22 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab—2/4 (50%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventTrastuzumab
AnaemiaBlood and lymphatic system disorders1/4
Deep vein thrombosisBlood and lymphatic system disorders1/4
DiarrhoeaGastrointestinal disorders1/4
DyspnoeaRespiratory, thoracic and mediastinal disorders1/4
FatigueGeneral disorders1/4
GastroenteritisInfections and infestations1/4
MelaenaGastrointestinal disorders1/4
Pulmonary tuberculosisInfections and infestations1/4
VomitingGastrointestinal disorders1/4
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTrastuzumab
DiarrhoeaGastrointestinal disorders1/4
Mouth ulcerationGastrointestinal disorders1/4
FatigueGeneral disorders1/4
PyrexiaGeneral disorders1/4
Jaundice cholestaticHepatobiliary disorders1/4
FuruncleInfections and infestations1/4
Blood creatinine increasedInvestigations1/4
Neutrophil count decreasedInvestigations1/4
Neuropathy peripheralNervous system disorders1/4
ParaesthesiaNervous system disorders1/4

Baseline characteristics

Intent-to-treat (ITT) population included all participants who received at least 1 dose of study drug and did not report any major protocol violation.

Age, Continuous
Age, Continuous(years)Trastuzumab
Mean64.8 ± 7.27
Gender
Gender(Participants)Trastuzumab
Female1
Male3
08

Study locations

6 sites
  • New Delhi, Delhi 110085, India
  • Bangalore, Karnataka 560027, India
  • Bangalore, 560029, India
  • Nagpur, 440012, India
  • Noida, 201 301, India
  • Vishakpatnam, 530002, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2010
First posted
Dec 15, 2010
Start
Jun 2011
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results first posted
Mar 14, 2016
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01260194
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 15, 2010
Start date
Jun 2011
Primary completion
Jan 2015
Completion
Jan 2015
Results posted
Mar 14, 2016
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion